Kyntra Bio vs Ovid Therapeutics
Ovid Therapeutics reported revenue of $7 million in fiscal 2025, about the same as Kyntra Bio's $6 million in fiscal 2025. Kyntra Bio's revenue fell 78.3% in its latest year, and Ovid Therapeutics' grew 1181.3%. Kyntra Bio had an operating margin of -712.7%, against -585.2% at Ovid Therapeutics. Free cash flow was −$5 million at Kyntra Bio and −$38 million at Ovid Therapeutics.
Side by side
| Kyntra Bio | Ovid Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $6M | $7M |
| Revenue growth | −78.3% | 1,181.3% |
| Revenue growth a year, last 5 years | −48.5% | −10.3% |
| Gross margin | 91.4% | — |
| Operating margin | −712.7% | −585.2% |
| Net margin | 2,848.6% | −240.1% |
| Free cash flow | −$5M | −$38M |
| Free cash flow margin | −74.7% | −528.6% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 1.0% | — |
| Last close | $1.83 | $2.34 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $19,852, sold $0 | sold $29,285 |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Kyntra BioOvid Therapeutics
Operating margin
Percent of revenue
Kyntra BioOvid Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Kyntra BioOvid Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Kyntra Bio and Ovid Therapeutics pages.